ASCO24 Summary: Latest data on ctDNA as a patient selection and early efficacy marker in drug development

Latest data on ctDNA as a patient selection and early efficacy marker for gynecologic cancers

Natera Analogy of Radon Testing to Signatera testing - social - d1 - with captions

Natera Signatera gave me more time - social - d1 - with captions

Brent's Story

Using ctDNA to help inform the management of patients with low-risk colorectal cancer (with subtitles)

Using ctDNA to help inform the management of patients with low-risk colorectal cancer

Using ctDNA to help inform the management of patients with locally advanced rectal cancer (with subtitles)

Using ctDNA to help inform the management of patients with locally advanced rectal cancer

The expanding role of ctDNA in colorectal cancer to optimize patient management

The expanding role of ctDNA in colorectal cancer to optimize patient management (with subtitles)

How ctDNA can transform interventional trial design for GI cancers

Seeing the Forest Through the Trees: How tumor informed MRD testing can illuminate the treatment pathway in GI cancer

Review recently presented MRD data in colorectal and pancreatic cancer, exploring the potential impact on patient care

Seeing the Forest Through the Trees: Using tumor-informed MRD testing to illuminate the treatment pathway in GI cancer

Personalized ctDNA testing to help guide treatment decisions in breast cancer

Webinar: Breast Cancer 2023 Data & Post-SABCS Summary

ctDNA in drug development for breast cancer Multiple studies have demonstrated that detection of molecular residual disease (MRD) is associated with poor prognosis in breast cancer. Ongoing prospectiv

Panel Discussion: How ctDNA Testing is Informing the Management of Patients With GI Cancer - Direct

Our experts will review real-world case studies showing when and where ctDNA can help inform shared decision-making.

Locate and Track: ctDNA Monitoring in NSCLC with Signatera

Learn about the clinical applications for Signatera in NSCLC across early stage and metastatic disease

Keith's Story

Listen in how one CRC patient and his physician used Signatera as a part of his treatment strategy to help identify an early signal that cancer may be lurking.